Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Reports Revenue, Earnings Gains in Q3

NEW YORK, Oct. 20 (GenomeWeb News) - Affymetrix today reported third-quarter revenues of $79.9 million, a 4.9 percent increase over revenues of $76.2 million in the third quarter of 2003.

 

Although the Santa Clara, Calif.-based firm fell short of analysts' expectations of third-quarter revenues of $86.8 million, it noted that product orders during the quarter exceeded product revenues by $9 million. More than $4 million of this amount is from arrays and reagents that exceeded the firm's inventory for those products. Affymetrix expects to ship those arrays and reagents early in the fourth quarter.

 

The firm's product and product-related revenues increased to $76.2 million in the quarter, up from $71.1 million in the third quarter of 2003. The sales included GeneChip array revenues of $37.5 million and instrument revenue of $16.4 million. Affymetrix noted that its installed base of GeneChip systems rose to more than 1,120 during the quarter.

 

Upon releasing its second-quarter results, Affymetrix had forecasted product and product-related revenues of $80 million to $85 million

 

Perhaps the most significant piece of news for Affymetrix during the quarter was the European Union clearance to market the firm's GeneChip platform for in vitro diagnostic purposes. It was the first marketing approval for Affymetrix and Roche under their collaboration to develop and sell molecular diagnostic products based on the GeneChip system. In tandem with Affymetrix's EU clearance, Roche received the CE Mark for its AmpliChip CYP450 drug-metabolism test.

 

For the full fiscal year, Affymetrix maintained its previous guidance for product and product-related revenues of $330 million to $335 million. However, the firm raised its earning-per-share guidance from $.60 to $.70.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.